A number of my constituents transferred from AstraZeneca to Avara Pharmaceuticals when the Avalon Pharmaceuticals site north of Bristol was sold. They did so because they were promised that if the business failed, they would still be entitled to their full AstraZeneca redundancy package. That has not happened and those workers are now being made redundant on statutory pay only, although AstraZeneca still has a legal contract with Avara to enforce that right, which expires in October. I have written to the Department for Business, Energy and Industrial Strategy and received a wholly unsatisfactory answer, and I have applied for an Adjournment debate four weeks in a row without success. Does the Leader of the House agree that the matter deserves ministerial attention, and that that should be given before the summer recess?